Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Nordberg, Janne ^a   Mpindi, John Patrick ^b   Iljin, Kristiina ^b   Pulliainen, Arto Tapio ^a   Kallajoki, Markku ^c   Kallioniemi, Olli ^b,d   Elenius, Klaus ^a,c,e   Elenius, Varpu ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; VASCULOTROPIN C;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CHILDHOOD CANCER; CONTROLLED STUDY; EPHA2 GENE; ERBB3 GENE; EWING SARCOMA; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; VEGFC GENE;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; CLUSTER ANALYSIS; DRUG APPROVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; RECEPTOR, ERBB-3; REPRODUCIBILITY OF RESULTS; RHABDOMYOSARCOMA, ALVEOLAR; SARCOMA, EWING;

EID: 84870790926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050819     Document Type: Article

References (45)

1. Watson R, (2005) EU supports testing for children's drugs. BMJ 330: 1348.
2. Sinha G, (2008) EU law mandates drug testing in children. J Natl Cancer Inst 100: 84-85.
3. Paolucci P, Jones KP, del Carmen Cano Garcinuno M, Catapano M, Iolascon A, et al. (2008) Challenges in prescribing drugs for children with cancer. Lancet Oncol 9: 176-183.
4. Wachtel M, Schäfer BW, (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36: 318-327.
5. Hynes NE, MacDonald G, (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
6. Balamuth NJ, Womer RB, (2010) Ewing's sarcoma. Lancet Oncol 11: 184-192.
7. Linabery AM, Ross JA, (2008) Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer 113: 2575-2596.
8. Thompson PA, Chintagumpala M (2012) Targeted Therapy in Bone and Soft Tissue Sarcoma in Children and Adolescents. Curr Oncol Rep.
9. Hettmer S, Wagers AJ, (2010) Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med 16: 171-173.
10. Landier W, Bhatia S, (2008) Cancer survivorship: a pediatric perspective. Oncologist 13: 1181-1192.
11. Messahel B, Hing S, Nash R, Jeffrey I, Pritchard-Jones K, (2005) Clinical features of molecular pathology of solid tumours in childhood. Lancet Oncol 6: 421-430.
12. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, et al. (2008) Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 9: R139.
13. Huang F, Reeves K, Han X, Fairchild C, Platero S, et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238.
14. Cho J, Shen H, Yu H, Li H, Cheng T, et al. (2011) Ewing sarcoma gene Ews regulates hematopoietic stem cell senescence. Blood 117: 1156-1166.
15. Funahashi Y, Yoshino Y, Hattori R, (2009) Ewing's sarcoma/primitive neuroectodermal tumor of the prostate. Int J Urol 16: 769.
16. Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, et al. (2000) A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 275: 8641-8649.
17. Mpindi JP, Sara H, Haapa-Paananen S, Kilpinen S, Pisto T, et al. (2011) GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. PLoS One 6: e17259.
18. Joensuu H, (2002) Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med Klin (Munich) 97Suppl 1: 28-30.
19. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, et al. (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67: 2800-2808.
20. Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, et al. (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28: 5174-5181.
21. Noguchi H, Sakamoto C, Wada K, Akamatsu T, Uchida T, et al. (1999) Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. Gastroenterology 117: 1119-1127.
22. Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, et al. (2010) De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology 57: 836-850.
23. Wykosky J, Debinski W, (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795-1806.
24. Genander M, Frisén J, (2010) Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol 22: 611-616.
25. Pasquale EB, (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
26. Surawska H, Ma PC, Salgia R, (2004) The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15: 419-433.
27. Campbell TN, Robbins SM, (2008) The Eph receptor/ephrin system: an emerging player in the invasion game. Curr Issues Mol Biol 10: 61-66.
28. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
29. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, et al. (2008) Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1198-1206.
30. Lohela M, Bry M, Tammela T, Alitalo K, (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
31. DuBois S, Demetri G, (2007) Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109: 813-819.
32. Edwards JR, Williams K, Kindblom LG, Meis-Kindblom JM, Hogendoorn PC, et al. (2008) Lymphatics and bone. Hum Pathol 39: 49-55.
33. Tammela T, Alitalo K, (2010) Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
34. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, et al. (2005) Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 11: 2364-2378.
35. Gerber HP, Ferrara N, (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680.
36. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, et al. (2008) The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68: 4754-4762.
37. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, et al. (2008) Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 581-587.
38. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, et al. (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27: 3133-3140.
39. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, et al. (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27: 3126-3132.
40. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
41. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
42. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
43. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, et al. (2005) Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23: 6172-6180.
44. Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, et al. (2009) Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27: 4599-4604.
45. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, et al. (2008) Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 26: 4921-4927.